In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Pfizer PFE underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

Pfizer’s CEO Albert Bourla has revamped sales tactics, leading to a 31% rise in U.S. sales of Nurtec migraine medication, reports The Wall Street Journal.

We recently published a list of 10 Most Profitable Value Stocks to Buy Now. In this article, we are going to take a look at ...

Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

It has been five years since the world was blown into the tumult of a lethal pandemic. Back then, deserted streets and ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...

Not long ago, it seemed that the days when LeBron James and Stephen Curry ran the NBA were over. Neither player had won a championship—or even appeared in the NBA Finals—since Curry’s ...

I don’t know of whom I’m more jealous, Lorne Michaels or Susan Morrison. The latter’s “Lorne” is one of the best biographies I’ve ever read. It’s as if she videotaped his life and ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... In 2023, brand-name obesity drugs brought in almost $6 billion. According to Forbes, Semaglutide, a market leader ...